Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
出版年份 2014 全文链接
标题
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
作者
关键词
Mild Cognitive Impairment, Amyloid Positron Emission Tomography, Early Clinical Development, Insoluble Fibril, Aseptic Meningoencephalitis
出版物
Alzheimers Research & Therapy
Volume 6, Issue 2, Pages 16
出版商
Springer Nature
发表日期
2014-03-25
DOI
10.1186/alzrt246
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
- (2013) Clifford R Jack et al. LANCET NEUROLOGY
- The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease
- (2013) Kaj Blennow et al. MEDICAL CLINICS OF NORTH AMERICA
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolated Amyloid-β(1–42) Protofibrils, But Not Isolated Fibrils, Are Robust Stimulators of Microglia
- (2012) Geeta S. Paranjape et al. ACS Chemical Neuroscience
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
- (2012) M. Scholl et al. NEUROLOGY
- Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
- (2012) Dag Sehlin et al. PLoS One
- A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
- (2011) S. Salloway et al. NEUROLOGY
- Pyroglutamate-Aβ: Role in the natural history of Alzheimer's disease
- (2010) Adam P. Gunn et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Amyloid -Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
- (2010) B. O'Nuallain et al. JOURNAL OF NEUROSCIENCE
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- Decreased Clearance of CNS -Amyloid in Alzheimer's Disease
- (2010) K. G. Mawuenyega et al. SCIENCE
- Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies
- (2009) A. J. Mitchell et al. ACTA PSYCHIATRICA SCANDINAVICA
- Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
- (2009) Bruno Vellas et al. Current Alzheimer Research
- Amyloid-β protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic mice
- (2009) Anna Lord et al. FEBS Journal
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
- An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
- (2009) Anna Lord et al. NEUROBIOLOGY OF DISEASE
- Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study
- (2009) A. Okello et al. NEUROLOGY
- Molecular genetics of Alzheimer's disease: An update
- (2008) Nathalie Brouwers et al. ANNALS OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started